CRISPR Therapeutics Balance Sheet Analysis

Assets, liabilities, and stockholders equity in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for CRISPR Therapeutics AG (CRSP) - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Current Assets
Cash and Cash Equivalents0.300.391.822.381.170.940.46
Short-Term Investments1.611.301.601.460.520.000.00
Cash & Short-Term Investments1.901.691.822.381.690.940.46
Accounts Receivable0.030.210.010.000.010.000.00
Inventory0.000.000.000.000.000.000.00
Other Current Assets0.010.010.030.020.020.010.00
Total Current Assets1.941.911.852.421.720.990.47
Non-Current Assets
Property, Plant & Equipment (Net)0.280.310.320.310.090.070.02
Long-Term Investments0.000.000.050.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.00
Other Non-Current Assets0.030.010.020.020.020.010.00
Total Non-Current Assets0.300.320.390.330.110.080.02
Total Assets2.242.232.242.751.831.070.49
Current Liabilities
Accounts Payable0.010.040.110.110.010.040.03
Short-Term Debt0.020.000.000.000.000.000.00
Accrued Liabilities0.040.040.080.080.050.000.00
Deferred Revenue0.000.000.000.000.000.000.00
Other Current Liabilities0.050.010.000.000.010.010.00
Total Current Liabilities0.090.110.120.120.090.060.03
Non-Current Liabilities
Long-Term Debt0.210.220.230.210.050.040.00
Other Non-Current Liabilities0.000.000.010.010.010.010.00
Total Non-Current Liabilities0.220.240.250.230.070.070.07
Total Liabilities0.310.350.370.350.160.130.10
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.00
Retained Earnings-1.37-1.00-0.86-0.20-0.57-0.22-0.29
Accumulated Other Comprehensive Income0.000.00-0.02-0.010.000.000.00
Treasury Stock0.000.000.000.000.000.000.00
Additional Paid-in Capital3.292.882.732.602.241.160.68
Shares Outstanding0.090.080.080.080.000.000.00
Total Stockholders' Equity1.931.881.882.401.660.940.39
Total Liabilities & Equity2.242.232.242.751.831.070.49